EIQ.AX is trading at $1.53 (6% down) following an A$110m institutional placement and a sharp pullback from early-July gains.

  • The stock has retreated from a high of $1.75 on July 2, 2026, amid a trading halt and significant capital markets activity.
  • Market focus remains on a potential FDA clearance catalyst for the company's EchoSolv product.
  • The decline follows a period of strong performance, as investors digest the impact of the recent A$110 million capital raise.